TG Therapeutics, Inc. (TGTX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
TG Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 52.90 · gapped above the open, then crossed back over prior close. High/low 54.10 at 8:00 am ET, 52.69 at 3:15 pm ET.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
8 readings, 4 filed under bull and 4 under bear. Every figure is ours; the model chose the side.
the bull case· 4
8
disclosed supplier and customer ties in SEC filings
sec filingsedgar4
funds on file reporting a position in TGTX
n-portas of Jun 30 '26431
managers reporting a position in thirteen f filings
13fJun 30 '26+3.49%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 4
11 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '261.09%
of State Street SPDR S and P Biotech ETF assets as largest fund weight
n-portJun 30 '264 of 7
recent reports where the move came in under the options implied range
earnings historyimplied vs realized33
managers whose positions together make up four fifths of the reported value
13fJun 30 '26The model filed each reading under bull or bear and wrote its caption; a caption carrying a digit is replaced by our own phrase, so every figure on this zone is ours. Built Sep 16 '26 against the Nov 9 '26 report; rebuilt when that date rolls. Not a forecast, not advice.
Of the 6 companies TG Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 149 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
431 managers report a position worth $6.3B between them, and 33 of them hold 80% of it.
tall tick = annual report · 1 on record
TGTX (TG Therapeutics, Inc.) has 7 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: FBIO +0.40%, in healthcare.